spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

3P Biopharmaceuticals


• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use
• Beginning of Phase I clinical trial in a group of 10 patients

[Pamplona, 20 December 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and Viscofan BioEngineering, the business unit within the Viscofan Group), go one step further in an innovative cell therapy product.

Cardiomesh is the name of the project to develop and manufacture the VB-C01, an innovative biopharmaceutical drug owned by Viscofan, to treat patients with ischemic heart disease.

In fact, the first implantation of the combined drug VB-C01 has already been successfully performed in a patient with chronic heart failure of ischemic origin at the Gregorio Marañón Hospital in Madrid.

The treatment lies in placing a collagen membrane, in the patient's heart affected area, similar to a patch, which contains allogeneic stem cells derived from adipose tissue (that are responsible for contributing to the regeneration of the infarcted tissue). In short, this is an Advanced Therapy Medicinal Product (ATMP).

This operation marks the beginning of the clinical trial whose goal is to evaluate the safety and tolerance of a new treatment for myocardial lesions in a group of 10 patients. This first part of the clinical development is being carried out at the Gregorio Marañón Hospital and the Clinic University of Navarra, which are contributing in the research of this innovative technique.

Dámaso Molero, 3P Biopharmaceuticals CEO, explained: "It's exciting to be part of an innovative project in advanced cell therapy as Cardiomesh, which aims to treat heart failure patients and help improve their lives”.

The research to produce a regenerative therapy device is part of a Viscofan product diversification line aimed at the medical field, with collagen as the common denominator: "Our collagen membrane has unique properties that allow the implanted cells to remain active for longer in a highly manageable support", explains Lluis Quintana, Director of the Bioengineering unit at Viscofan.

CARDIOMESH PROJECT:

The collaboration between both companies from Navarra began in 2015 with the process transfer to 3P Biopharmaceuticals after years of research at the University of Navarra and Viscofan BioEngineering. 3P Biopharmaceuticals, which has an exclusive area of cell therapy, carried out the implementation, the scaling-up, the validation and certification of the process under GMP conditions. Currently, 3P is responsible for manufacturing the drug VB-C01 for the clinical trial Phase I.

Ischemic cardiomyopathies, being part of the cardiovascular diseases and the main cause of death worldwide, account 33% of deaths in developed countries for people over 35’s.

In response, many palliative medical treatments have been developed, such as therapies with cardiac devices or heart transplants, which have reduced the number of deaths from acute myocardial infarctions. But at the same time, have contributed to an epidemic of chronic heart diseases of ischemic origin.

Therefore, the Cardiomesh project introduces, within the current paradigm of cardiovascular treatment, the development of a regenerative therapy, through the manufacture of an industrial scale an advanced therapy product with unique properties.

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P Biopharmaceuticals offers solutions at all stages of biologics development, from initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market.

Further information: http://www.3pbio.com/

About Viscofan BioEngineering

The Viscofan Group is a world leader in the manufacture of packaging for the food industry. The Group has a commercial presence in more than 100 countries and leads the world market being the only global producer offering the main packaging technologies available: cellulose, collagen, fibrous, vegetable and plastic. Viscofan BioEngineering is a business unit located in Germany, the centre of excellence for collagen within the Viscofan Group. The production centre has more than 80 years of experience extracting and processing collagen from cow hides. Its activity is based on the production of Type 1 collagen-based materials for biomedical applications on an industrial scale.


3P Biopharmaceuticals contact:
Isabel García, Communication and Marketing
Tel. + 34 948 346 480 | e-mail: igarcia@3pbio.com
phone +34 948 34 64 80
web https://www.3pbio.com/
email Polgono Mochol, C/ Mochol 2, 31110 Noin, Navarra, Spain
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Cognizant Shared Investigator Platform for Life Sciences Reaches Major Milestone in Accelerating Drug Discovery

Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries. The platform has become increasingly critical to progressing clinical trials as prevailing social distancing norms have significantly curtailed in-person collaboration.
More info >>


White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement